All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
ASH 2024: Top abstracts in MM and other plasma cell dyscrasias
Bookmark this article
To help navigate the exciting content being presented at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, December 7–10, 2024, San Diego, US, the Multiple Myeloma Hub Steering Committee have provided their recommendations for the top abstracts to look out for in multiple myeloma and other plasma cell dyscrasias.
Newly diagnosed multiple myeloma
|
Abstract # |
Title |
Speaker |
Date and time (PT) |
|
Optimal MRD-Based Endpoint in the Setting of Upfront Quadruplets (QUADs) to Support Response-Adapted Treatment Cessation in Newly Diagnosed Multiple Myeloma (NDMM) |
Smith Giri |
Saturday, December 7, 2024, 15:00 |
|
|
Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial |
Sonja Zweegman |
Saturday, December 7, 2024, 16:15 |
|
|
Implications of MRD Progression in Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Therapy and Autologous Stem Cell Transplantation |
Luciano J. Costa |
Saturday, December 7, 2024, 16:30 |
|
|
Reevaluating the IMWG Multiple Myeloma Complete Response Criterion in the Era of Mass Spectrometry: A Critical Analysis |
Noemi Puig |
Sunday, December 8, 2024, 10:00 |
|
|
Phase 2 Study of Teclistamab-Based Induction Regimens in Patients with Transplant-Eligible (TE) Newly Diagnosed Multiple Myeloma (NDMM): Results from the GMMG-HD10/DSMM-XX (MajesTEC-5) Trial |
Marc S. Raab |
Sunday, December 8, 2024, 09:30 |
|
|
Phase 3 Study of Teclistamab (Tec) in Combination with Lenalidomide (Len) and Tec Alone Versus Len Alone in Newly Diagnosed Multiple Myeloma (NDMM) As Maintenance Therapy Following Autologous Stem Cell Transplantation (ASCT): Safety Run-in (SRI) Results from the Majestec-4/EMN30 Trial |
Elena Zamagni |
Sunday, December 8, 2024, 09:45 |
|
|
Phase I Study of Belantamab Mafodotin in Combination with Standard of Care in Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Dreamm-9 Updated Interim Analysis |
Saad Z. Usmani |
Sunday, December 8, 2024, 10:30 |
|
|
Daratumumab Plus Lenalidomide (D-R) Versus Lenalidomide (R) Alone As Maintenance Therapy in Newly Diagnosed Multiple Myeloma (NDMM) after Transplant: Analysis of the Phase 3 Auriga Study Among Clinically Relevant Subgroups |
Laahn Foster |
Sunday, December 8, 2024, 17:00 |
|
|
GEM2017Fit Phase 3 Trial in Fit Elderly Patients (Aged 65-80) with Newly Diagnosed Myeloma: Impact of Daratumumab at Induction and/or Consolidation |
Maria- Victoria Mateos |
Sunday, December 8, 2024, 17:45 |
|
|
Isatuximab, Lenalidomide, Bortezomib and Dexamethasone Induction Therapy for Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Final Progression-Free Survival Analysis of Part 1 of an Open-Label, Multicenter, Randomized, Phase 3 Trial (GMMG-HD7) |
Hartmut Goldschmidt |
Monday, December 9, 2024, 10:30 |
|
|
The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma |
Salomon Manier |
Monday, December 9, 2024, 11:45 |
Relapsed/ refractory multiple myeloma
|
Abstract # |
Title |
Speaker |
Date and time (PT) |
|
Previous HDM/ASCT Adversely Impacts PFS with BCMA-Directed CAR T-Cell Therapy in Multiple Myeloma |
Joshua Gustine |
Saturday, December 7, 2024, 09:30 |
|
|
24-Hour Urine Testing Does Not Add Value to Multiple Myeloma Response Assessments: A Secondary Analysis of BMT CTN 0702 |
Rahul Banerjee |
Saturday, December 7, 2024, 10:00 |
|
|
Eliminating the Need for Sequential Confirmation of Response in Multiple Myeloma |
Jean-Sébastien Claveau |
Saturday, December 7, 2024, 10:30 |
|
|
Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study |
Heloise Cheruvalath |
Saturday, December 7, 2024, 14:45 |
|
|
Soluble B-Cell Maturation Antigen Levels for Disease Monitoring in Oligo- and Non-Secretory Relapsed Multiple Myeloma |
Daisuke Ikeda |
Saturday, December 7, 2024, 17:15 |
|
|
Teclistamab, Daratumumab, and Pomalidomide in Patients with Relapsed/Refractory Multiple Myeloma: Results from the Majestec-2 Cohort a and Trimm-2 Studies |
Anita D'Souza |
Sunday, December 8, 2024, 10:30 |
|
|
Mezigdomide (MEZI) in Novel-Novel Combinations for Relapsed or Refractory Multiple Myeloma (RRMM): Preliminary Results from the CA057-003 Trial |
Luciano J. Costa |
Sunday, December 8, 2024, 17:30 |
|
|
Belantamab Mafodotin, Bortezomib, and Dexamethasone Vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Overall Survival Analysis and Updated Efficacy Outcomes of the Phase 3 Dreamm-7 Trial |
Vania Hungria |
Monday, December 9, 2024, 11:15 |
|
|
Pre-Apheresis Prediction of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma |
Kai Rejeski |
Monday, December 9, 2024, 14:45 |
|
|
Comprehensive Analysis of Pre-Treatment Biomarkers Associated with Toxicity and Durable Responses in Idecabtagene Vicleucel Therapy for Relapsed/Refractory Multiple Myeloma |
Doris K. Hansen |
Monday, December 9, 2024, 15:00 |
|
|
Outcomes of Teclistamab (Tec) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with Prior Exposure to BCMA-Directed Therapy (BCMA-DT): A Multicenter Study from the U.S. Multiple Myeloma Immunotherapy Consortium |
Danai Dima |
Monday, December 9, 2024, 15:15 |
|
|
Biological and Clinical Significance of Endogenous and Chimeric Antigen Receptor (CAR) T Cell Immune Profiling in Relapsed/Refractory Multiple Myeloma (RRMM) Patients |
Bruno Paiva |
Monday, December 9, 2024, 16:00 |
|
|
Efficacy and Safety with Extended Follow-up in a Phase 1 Study of BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Heavily Pretreated Relapsed/Refractory (RR) Multiple Myeloma (MM) |
Susan Bal |
Monday, December 9, 2024, 15:30 |
|
|
Talquetamab Bridging: Paving the Way to B-Cell Maturation Antigen (BCMA) CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma (RRMM) |
Binod Dhakal |
Monday, December 9, 2024, 14:45 |
|
|
Tocilizumab Prophylaxis for Patients with Relapsed or Refractory Multiple Myeloma Treated with Teclistamab, Elranatamab or Talquetamab |
Andrew Kowalski |
Monday, December 9, 2024, 15:00 |
|
|
Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma |
Emma Searle |
Monday, December 9, 2024, 17:00 |
|
|
Mezigdomide (MEZI) Plus Dexamethasone (DEX) and Bortezomib (BORT) or Carfilzomib (CFZ) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from the CC-92480-MM-002 Trial |
Irwindeep Sandhu |
Monday, December 9, 2024, 17:30 |
|
|
First Results of a Phase 1, First-in-Human, Dose Escalation Study of ISB 2001, a BCMAxCD38xCD3 Targeting Trispecific Antibody in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) |
Hang Quach |
Monday, December 9, 2024, 17:45 |
|
|
Efficacy of HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma |
Eyal Lebel |
Monday, December 9, 2024, 17:15 |
|
|
Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or Refractory Multiple Myeloma: Preliminary Results from the IMMagine-1 Trial |
Ciara Louise Freeman |
Monday, December 9, 2024, 17:30 |
|
|
Ciltacabtagene Autoleucel (Cilta-cel) Vs Standard of Care (SoC) in Patients with Lenalidomide (Len)-Refractory Multiple Myeloma (MM) after 1-3 Lines of Therapy: Minimal Residual Disease (MRD) Negativity in the Phase 3 Cartitude-4 Trial |
Rakesh Popat |
Monday, December 9, 2024, 17:45 |
|
|
Frailty-Based Outcomes with Bispecific Antibodies in Older Patients with Multiple Myeloma |
Nadine Abdallah |
Monday, December 9, 2024, 18:00 |
Other plasma cell dyscrasias
|
Abstract # |
Title |
Speaker |
Date and time (PT) |
|
Longitudinal Single-Cell Immune Profiling Reveals Distinct Dynamics of Response to Teclistamab in Patients with High-Risk Smoldering Myeloma Compared to Relapsed-Refractory Multiple Myeloma |
Nayda Bidikian |
Sunday, December 8, 2024, 09:45 |
|
|
Phase 3 Randomized Study of Daratumumab Monotherapy Versus Active Monitoring in Patients with High-Risk Smoldering Multiple Myeloma: Primary Results of the Aquila Study |
Meletios-Athanasios Dimopoulos |
Monday, December 9, 2024, 11:30 |
|
|
Subcutaneous Daratumumab (DARA) + Bortezomib, Cyclophosphamide, and Dexamethasone (VCd) in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: Overall Survival and Final Major Organ Deterioration Progression-Free Survival Results from the Phase 3 Andromeda Study |
Efstathios Kastritis |
Monday, December 9, 2024, 15:15 |
|
|
Venetoclax Plus Dexamethasone As First-Line Treatment for t(11; 14) Light-Chain Amyloidosis: Preliminary Result of a Phase II Prospective, Multicenter, Single-Arm Study |
Kaini Shen |
Monday, December 9, 2024, 15:45 |
|
|
Early Safety and Efficacy of CAR-T Cell Therapy in Precursor Myeloma: Results of the CAR-PRISM Study Using Ciltacabtagene Autoleucel in High-Risk Smoldering Myeloma |
Omar Nadeem |
Monday, December 9, 2024, 16:30 |
More about...
Your opinion matters
2 votes - 43 days left ...
Related articles
Newsletter
Subscribe to get the best content related to multiple myeloma delivered to your inbox